News headlines about Merrimack Pharmaceuticals (NASDAQ:MACK) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.8730961515855 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several brokerages have recently weighed in on MACK. ValuEngine downgraded shares of Merrimack Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, October 2nd. Robert W. Baird reiterated a “hold” rating and set a $15.00 price objective on shares of Merrimack Pharmaceuticals in a research note on Friday, October 13th. Finally, Zacks Investment Research downgraded shares of Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th.
Merrimack Pharmaceuticals (NASDAQ:MACK) traded down $0.10 during midday trading on Friday, reaching $10.74. 100,754 shares of the company’s stock were exchanged, compared to its average volume of 181,500. Merrimack Pharmaceuticals has a 12-month low of $10.04 and a 12-month high of $39.90. The company has a quick ratio of 3.35, a current ratio of 3.35 and a debt-to-equity ratio of 0.45. The company has a market cap of $143.20, a P/E ratio of -1.47 and a beta of 1.72.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/13/merrimack-pharmaceuticals-mack-getting-somewhat-positive-press-coverage-study-finds.html.
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
What are top analysts saying about Merrimack Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merrimack Pharmaceuticals and related companies.